IP Library › Granted Patent US 12,480,950
Granted Patent B2
US 12,480,950 · App. 16/280,953 · Granted Nov 25, 2025

AKT-specific capture agents, compositions, and methods of using and making

Inventors: James R. Heath (South Pasadena, CA); Arundhati Nag (Pasadena, CA); Samir Das (Pasadena, CA); Kaycie M. Deyle (Sylmar, CA); Steven Wesley Millward (Monrovia, CA); Paul Edward Kearney (Seattle, WA)
Assignees: Regeneron Pharmaceuticals, Inc.; California Institute of Technology
G01N33/57449A61K38/08A61K49/0043A61K49/0056A61K51/08C07K7/02C07K14/001C12N15/1058C12Q1/485C12Q1/6804G01N33/573G01N33/5748G01N33/57496A61K38/00G01N2333/91205G01N2333/91215
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,480,950
App. No.
16/280,953
Granted
Nov 25, 2025
Kind
B2
Abstract

The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.

Claims (51)

1 . A method of identifying an anchor ligand to an epitope of interest, the method comprising:

contacting a polypeptide fragment with a plurality of candidate peptides, wherein the polypeptide fragment comprises the epitope, wherein the epitope is modified or substituted with (a) a group comprising an azido or acetylene group and (b) a label, wherein the candidate peptides all comprise an acetylene group if the epitope has an azido group or an azido group if the epitope has an acetylene group; and

incubating the polypeptide fragment and the candidate peptides to allow formation of a triazole linkage between the polypeptide fragment and one of the candidate peptides, wherein a candidate peptide that forms a triazole linkage with the polypeptide fragment is identified as the anchor ligand.

2 . The method of claim 1 , wherein the epitope is a distinct molecular surface of a target.

3 . The method of claim 1 , wherein the polypeptide fragment provides a catalytic scaffold for promoting the covalent coupling of the azido and acetylene groups to form the triazole linkage.

4 . The method of claim 1 , wherein the azido group and the acetylene group on the polypeptide fragment and the candidate peptides can react to form a triazole linkage between the polypeptide fragment and one of the candidate peptides.

5 . The method of claim 1 , wherein the group comprising an azido or acetylene group is an artificial amino acid.

6 . The method of claim 5 , wherein the artificial amino acid is propargylglycine (Pra).

7 . The method of claim 1 , wherein the epitope comprises a phosphorylated amino acid, wherein the group comprising an azido or acetylene group is a metalorganic molecule that selectively binds to the phospho group on the phosphorylated amino acid.

8 . The method of claim 7 , wherein the metalorganic molecule comprises the label.

9 . The method of claim 8 , wherein the label is biotin.

10 . The method of claim 7 , wherein the metalorganic molecule comprises an azido group.

11 . The method of claim 1 , wherein the label is biotin.

12 . The method of claim 1 further comprising:

selecting a candidate peptide linked to the polypeptide fragment via a triazole linkage as the anchor ligand; and

sequencing the anchor ligand.

13 . The method of claim 12 , wherein the candidate peptide is selected by selecting labeled candidate peptides.

14 . The method of claim 1 , wherein the epitope is an epitope of a target protein, wherein the method further comprises testing the anchor ligand for binding to the target protein.

15 . The method of claim 1 further comprising identifying a secondary ligand.

16 . The method of claim 15 , wherein the secondary ligand is identified by:

contacting an anchor ligand selection block and a plurality of second candidate peptides with a target comprising a second epitope, wherein the anchor ligand selection block comprises the anchor ligand and an azido group or an acetylene group, and wherein the second candidate peptides all comprise an acetylene group if the anchor ligand selection block has an azido group or an azido group if the anchor ligand selection block has an acetylene group;

incubating the anchor ligand selection block, the second candidate peptides, and the target to form a capture agent biligand by forming a triazole linkage between the anchor ligand selection block and one of the second candidate peptides, wherein the azido and acetylene group of the anchor ligand selection block and the second candidate peptide are brought in close proximity by binding to the target, wherein a second candidate peptide that forms a triazole linkage with the anchor ligand selection block is identified as the secondary ligand.

17 . The method of claim 16 , wherein the target is the polypeptide fragment.

18 . The method of claim 16 , wherein the target is a target protein.

19 . The method of claim 16 , wherein the second epitope is a distinct molecular surface of a target.

20 . The method of claim 16 further comprising:

selecting a second candidate peptide linked to the anchor ligand selection block via a triazole linkage as the secondary ligand; and

sequencing the secondary ligand.

21 . The method of claim 20 , wherein the second candidate peptide is selected by selecting labeled second candidate peptides.

22 . The method of claim 15 further comprising identifying a tertiary ligand.

23 . The method of claim 22 , wherein the tertiary ligand is identified by:

contacting a biligand selection block and a plurality of third candidate peptides with a target comprising a third epitope, wherein the biligand selection block comprises the anchor ligand, the secondary ligand, and an azido group or an acetylene group, and wherein the third candidate peptides all comprise an acetylene group if the biligand selection block has an azido group or an azido group if the biligand selection block has an acetylene group;

incubating the biligand selection block, the third candidate peptides, and the target to form a capture agent triligand by forming a triazole linkage between the biligand selection block and one of the third candidate peptides, wherein the azido and acetylene group of the biligand selection block and the third candidate peptide are brought in close proximity by binding to the target, wherein a third candidate peptide that forms a triazole linkage with the biligand selection block is identified as the tertiary ligand.

24 . The method of claim 23 , wherein the target is the polypeptide fragment.

25 . The method of claim 23 , wherein the target is a target protein.

26 . The method of claim 23 , wherein the third epitope is a distinct molecular surface of a target.

27 . The method of claim 23 further comprising:

selecting a third candidate peptide linked to the biligand selection block via a triazole linkage as the tertiary ligand; and

sequencing the tertiary ligand.

28 . The method of claim 27 , wherein the third candidate peptide is selected by selecting labeled third candidate peptides.

29 . The method of claim 22 further comprising identifying a higher order ligand.

30 . The method of claim 29 , wherein the higher order ligand is identified by repeating the following steps as many times as needed to identify the higher order ligand:

contacting an n-order ligand selection block and a plurality of nth candidate peptides with a target comprising an n-order epitope, wherein the n-order ligand selection block comprises the anchor ligand, the secondary ligand, the tertiary ligand, any higher order ligands identified in prior repetitions, and an azido group or an acetylene group, and wherein the nth candidate peptides all comprise an acetylene group if the n-order ligand selection block has an azido group or an azido group if the n-order ligand selection block has an acetylene group;

incubating the n-order ligand selection block, the nth candidate peptides, and the target to form a capture agent higher-order ligand by forming a triazole linkage between the n-order ligand selection block and one of the nth candidate peptides, wherein the azido and acetylene group of the n-order ligand selection block and the nth candidate peptide are brought in close proximity by binding to the target, wherein an nth candidate peptide that forms a triazole linkage with the n-order ligand selection block is identified as the higher-order ligand.

31 . The method of claim 30 , wherein the target is the polypeptide fragment.

32 . The method of claim 30 , wherein the target is a target protein.

33 . The method of claim 30 , wherein the n-order epitope is a distinct molecular surface of a target.

34 . The method of claim 30 further comprising:

selecting a nth candidate peptide linked to the n-order ligand selection block via a triazole linkage as the higher-order ligand; and

sequencing the higher-order ligand.

35 . The method of claim 34 , wherein the nth candidate peptide is selected by selecting labeled nth candidate peptides.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2024
From: INDI MOLECULAR, INC.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 069456/0201 →
CONFIRMATORY LICENSE Recorded Nov 4, 2022
From: CALIFORNIA INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061883/0781 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2021
From: INDI MOLECULAR, INC.
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 056564/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2019
From: INTEGRATED DIAGNOSTICS, INC.
To: INDI MOLECULAR, INC.
Reel/Frame 049891/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2019
From: HEATH, JAMES R.; NAG, ARUNDHATI; DAS, SAMIR; DEYLE, KAYCIE M.; MILLWARD, STEVEN WESLEY; KEARNEY, PAUL
To: INTEGRATED DIAGNOSTICS, INC.
Reel/Frame 048396/0471 →
Continuity (6)
Continuation 14949236 · Nov 23, 2015
Continuation 13546575 · Jul 11, 2012
Provisional Application 61598614 · Feb 14, 2012
Provisional Application 61597628 · Feb 10, 2012
Provisional Application 61506560 · Jul 11, 2011
Related Publication 20190177367A1 · Jun 13, 2019
References Cited (210)
US 4899755A · Lauffer · 1990 [cited by applicant]
US 5474756A · Tweedle · 1995 [cited by applicant]
US 5547668A · Kranz · 1996 [cited by applicant]
US 5846519A · Tweedle · 1998 [cited by applicant]
US 6143274A · Tweedle · 2000 [cited by applicant]
US 6566088B1 · McKnight · 2003 [cited by applicant]
US 8710180B2 · Pitram · 2014 [cited by applicant]
US 8841083B2 · Heath · 2014 [cited by applicant]
US 8906830B2 · Agnew · 2014 [cited by applicant]
US 9188584B2 · Agnew · 2015 [cited by applicant]
US 9221889B2 · Pitram · 2015 [cited by applicant]
US 9239332B2 · Heath · 2016 [cited by applicant]
US 9913875B2 · Farrow · 2018 [cited by applicant]
US 10598671B2 · Heath · 2020 [cited by applicant]
US 11007245B2 · Farrow · 2021 [cited by applicant]
US 20060153839A1 · Mohamed · 2006 [cited by applicant]
US 20100009896A1 · Agnew · 2010 [cited by applicant]
US 20110009896A1 · Forsell et al. · 2011 [cited by applicant]
US 20110177109A1 · Smith, III · 2011 [cited by applicant]
US 20110263515A1 · Agnew · 2011 [cited by applicant]
US 20120202219A1 · Agnew · 2012 [cited by applicant]
US 20120252071A1 · Greif · 2012 [cited by applicant]
US 20130156692A1 · Pitram · 2013 [cited by applicant]
US 20140302998A1 · Heath · 2014 [cited by applicant]
US 20150099658A1 · Pfeilsticker · 2015 [cited by applicant]
US 20150132314A1 · Farrow · 2015 [cited by applicant]
US 20150344523A1 · Deyle · 2015 [cited by applicant]
US 20160331800A1 · Farrow · 2016 [cited by applicant]
US 20180364253A1 · Agnew · 2018 [cited by applicant]
US 20200407712A1 · Boyd · 2020 [cited by applicant]
US 20220211648A1 · Agnew · 2022 [cited by applicant]
EP 2719706 · 2014 [cited by applicant]
JP 2005198643 · 2005 [cited by applicant]
WO 1986006605 · 1986 [cited by applicant]
WO 1991003200 · 1991 [cited by applicant]
WO 1995028179 · 1995 [cited by applicant]
WO 1995028967 · 1995 [cited by applicant]
WO 1996023526 · 1996 [cited by applicant]
WO 1997036619 · 1997 [cited by applicant]
WO 1998018496 · 1998 [cited by applicant]
WO 1998018497 · 1998 [cited by applicant]
WO 1998046612 · 1998 [cited by applicant]
WO 1999017809 · 1999 [cited by applicant]
WO 9921576 · 1999 [cited by applicant]
WO 2002083064A2 · 2002 [cited by applicant]
WO WO2002083064 · 2002 [cited by applicant]
WO 03006620 · 2003 [cited by applicant]
WO 2005113762A1 · 2005 [cited by applicant]
WO WO2005113762 · 2005 [cited by applicant]
WO 2007050963 · 2007 [cited by applicant]
WO 2009051555 · 2009 [cited by applicant]
WO 2009105746A2 · 2009 [cited by applicant]
WO WO2009105746 · 2009 [cited by applicant]
WO 2009155420 · 2009 [cited by applicant]
WO 2010135431 · 2010 [cited by applicant]
WO 2011057347 · 2011 [cited by applicant]
WO 2012106651 · 2012 [cited by applicant]
WO 2012106671 · 2012 [cited by applicant]
WO 2013009869 · 2013 [cited by applicant]
WO 2013034982 · 2013 [cited by applicant]
WO 2014056813 · 2014 [cited by applicant]
WO 2014074907 · 2014 [cited by applicant]
WO 2014205317 · 2014 [cited by applicant]
WO 2017011769 · 2017 [cited by applicant]
WO 2017176769 · 2017 [cited by applicant]
WO 2018064597 · 2018 [cited by applicant]
WO 2018111580 · 2018 [cited by applicant]
WO 2018170096 · 2018 [cited by applicant]
WO 2018200551 · 2018 [cited by applicant]
WO 20200127227 · 2020 [cited by applicant]
WO 2020127227 · 2020 [cited by applicant]
Agnew, et al., “Protein-Catalyzed Capture Agents”, [cited by applicant]
Agnew, et al., “Iterative in Situ Click Chemistry Creates Antibody-like Protein-Capture Agents”, [cited by applicant]
Alexander, et al., “Intracranial black-blood MR angiography with high-resolution 3D fast spin echo”, Magn. [cited by applicant]
Altschul, et al, “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, [cited by applicant]
Artali, et al., “A molecular dynamics study of human serum albumin binding sites”, [cited by applicant]
Bianchi et al., “Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates”, [cited by applicant]
Boersma, “Gaining knowledge of single carbon chains”, [cited by applicant]
Chan, et al., “Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy”, [cited by applicant]
Chattopadhyay, et al., “Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers”, [cited by applicant]
Chauhan, et al. “The Taming of the Cell Penetrating Domain of the HIV Tat: Myths and Realities”, [cited by applicant]
Chen, et al., “Fusion protein linkers: property, design and functionality”, [cited by applicant]
Cheong, et al., “A patent review of IDO1 inhibitors for cancer”, [cited by applicant]
Choksi, et al., “A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model”, [cited by applicant]
Claverie, “Information enhancement methods for large scale sequence analysis”, [cited by applicant]
Coppock, et al., “Peptide-based protein capture agents with high affinity, selectivity, and stability as antibody replacements in bio detection assays”, [cited by applicant]
Das, et al., “A General Synthetic Approach for Designing Epitope Targeted Macrocyclic Peptide Ligands”, [cited by applicant]
Dieck, et al., “Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation”, [cited by applicant]
Edelman, et al., “Extracranial carotid arteries: evaluation with “black blood” MR angiography”, [cited by applicant]
Eiber, et al., “Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy”, [cited by applicant]
Farrow, et al., “Epitope Targeting of Tertiary Protein Structure Enables Target-Guided Synthesis of a Potent In-Cell Inhibitor of Botulinum Neurotoxin”, [cited by applicant]
Fisher, et al, “Trivalent Gd-DOTA reagents for modification of proteins”, [cited by applicant]
Fitzer-Attas, et al., “Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the Variable Domain recept”, [cited by applicant]
Gao, et al., “Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2”, [cited by applicant]
Gen Bank: AAH25715.1, “CD8a molecule [ [cited by applicant]
Goodrich, et al., “A quantitative study of ramped radio frequency, magnetization transfer, and slab thickness in three-dimensional time-of-flight magnetic resonance angiography in a patient population”, [cited by applicant]
Handl, et al., “Hitting multiple targets with multimeric ligands”, [cited by applicant]
Hill, et al., “Constraining Cyclic Peptides to Mimic Protein Structure Motifs”, [cited by applicant]
Hirai, et al., “MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo”, [cited by applicant]
Hudson, et al, “Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes”, [cited by applicant]
Josan, et al., “Cell-specific targeting by heterobivalent ligands”, [cited by applicant]
Lai, et al., “Epitope-Targeted Macrocyclic Peptide Ligand with Picomolar Cooperative Binding to Interleukin-17F”, [cited by applicant]
Li, et al., “Identification of the CD8 DE loop as a surface functional epitope. Implications for major histocompatibility complex class I binding and CD8 inhibitor design”, [cited by applicant]
Lin, et al., “Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway”, [cited by applicant]
Lindlsey, et al., “The P13K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors”, [cited by applicant]
Ma, et al., “A cyclic peptide-polymer probe for the detection of Clostridium botulinum neurotoxin serotype A”, [cited by applicant]
Mabry, et al., “Engineering of stable bispecific antibodies targeting IL-17 A and IL-23”, [cited by applicant]
Macraild et al., “Antibody Recognition of Disordered Antigens”, [cited by applicant]
Macraild et al., “Conformational Dynamics and Antigenicity in the Disordered Malaria Antigen Merozoite Surface Protein 2”, [cited by applicant]
Mamidyala et al., In situ click chemistry: probing the binding landscapes of biological molecules, [cited by applicant]
Manea, et al., “Antibody Recognition and Conformational Flexibility of a Plaque-Specific-Amyloid Epitope Modulated by Non-native Peptide Flanking Regions”, [cited by applicant]
Matsuura, “Identification of conformational neutralizing epitopes on the capsid protein of canine calicivirus”, [cited by applicant]
Melenhorst et el., “Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers”, [cited by applicant]
Merriam-Webster online definition of “correspond” downloaded Jun. 29, 2020 from internet, https://www.merriam-webster.com/dictionary/correspond (Year: 2020). [cited by applicant]
Meyers and Miller, “Optimal alignments in linear space”, [cited by applicant]
Millward, et al., “In situ click chemistry: from small molecule discovery to synthetic antibodies”, [cited by applicant]
Miossec, “Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice”, [cited by applicant]
Mor, et al., Mimicking the Structure of the V3 Epitope Bound to HIV-1 Neutralizing Antibodies, [cited by applicant]
Muller, et al., “DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid-Targeted 177Lu-Radionuclide Tumor Therapy in Mice”, [cited by applicant]
Nag et al., “A chemical epitope-targeting strategy for protein capture agents: the serine 474 epitope of the kinase Akt2”, [cited by applicant]
Pansca, et al., “Structural disorder in eukaryotes”, [cited by applicant]
Pfeilsticker, et al., “A cocktail of thermally stable, chemically synthesized capture agents for the efficient detection of anti-gp41 antibodies from human sera”, [cited by applicant]
Saito, et al., “Identification of anti-CD98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization”, [cited by applicant]
Schweinsberg, et al., “Novel glycated [99mTc (CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors”, Bioconjugate Chem., 19(12):2432-2439 (2008). [cited by applicant]
Son, et al., “New Cyclic Lipopeptides of the Iturin Class Produced by Saltern-Derived [cited by applicant]
Tang et al., “Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells”, [cited by applicant]
Tao, et al., “Expression, purification and identification of an immunogenic fragment in the ectodomain of prostate-specific membrane antigen”, [cited by applicant]
Todorova, et al., “Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induces after immunization with gene-based vaccines”, [cited by applicant]
Torres, et al., “A revolutionary therapeutic approach for psoriasis: bi specific biological agents”, [cited by applicant]
Wang, et al., “Epitope Mapping Using Phage-Display Random Fragment Libraries”, [cited by applicant]
Wang, et al., “Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90 Y-DOTA-EB-MCG”, [cited by applicant]
Wooldridge, et al., “Tricks with tetramers: how to get the most from multimeric peptide-MHC”, [cited by applicant]
Wootton, and Federhen, “Statistics of local complexity in amino acid sequences and sequences databases”, [cited by applicant]
Zhang, et al., “Structure and function of interleukin-17 family cytokines”, [cited by applicant]
Lindsey, et al., “The P13K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors”, Current Cancer Drug Targets, 8: 7-18 (2008). [cited by applicant]
Wang, et al., “Epitope Mapping Using Phage-Display Random Fragment Libraries”, Epitope Mapping Protocols, Methods in Molecular Biology, 524: 315-332 (2009). [cited by applicant]
European Patent Application No. 12811372.7, Office Action mailed Feb. 3, 2016, 6 pages. [cited by applicant]
Journal of Biological Chemistry, 2004, vol. 279, No. 51, p. 53407-53418. [cited by applicant]
Japanese Patent Application No. 2014-520277, Office Action mailed Mar. 29, 2016, 22 pages. [cited by applicant]
Milward, S.W et al.: “Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1”, JACS., vol. 133, No. 45, Sep. 30, 2011 (Sep. 30, 2011), pp. 18280-18288. [cited by applicant]
M. Subramanyam et al: “Inhibition of Protein Kinase Akt1 by Apoptosis Signal-regulating Kinase-1 (ASK1) Is Involved in Apoptotic Inhibition of Regulatory Volume Increase”, Journal of Biological Chemistry, vol. 285, No. … [cited by applicant]
Sarbassov D D et al: “Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex”, Science, American Association for the Advancement of Science, US, vol. 307, No. 5712, Feb. 18, 2005 (Feb. 18, 2005), pp. 1098-… [cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2012/046253, mailed Feb. 21, 2013. [cited by applicant]
Search Report with Search Opinion corresponding to European Patent Application No. 12811372, dated Jul. 1, 2015. [cited by applicant]
Agnew et al. (2009) “Iterative In Situ Click Chemistry Creates Antibody-like Protein-Capture Agents,” Angewandte Chemie Int. Ed. 48(27):4944-4948. [cited by applicant]
Altomare et al. (2005) “Perturbations of the AKT signaling pathway in human cancer,” Oncogene. 24:7455-7464. [cited by applicant]
Borrebaeck et al. (2000) “Antibodies in diagnostics—from immunoassays to protein chips,” Immunol. Today. 21 (8):379-382. [cited by applicant]
Carpten et al. (2007) “A transforming mutation in the pleckstrin homology domain of AKT1 in cancer,” Nature. 448:439-445. [cited by applicant]
Chothia et al. (1989) “Conformations of immunoglobulin hypervariable regions,” Nat. 342:877-883. [cited by applicant]
Cohen (2002) “Propotein kinases—the major drug targets of the twenty-first century?” Nat. Rev. Drug Discov. 1:309-315. [cited by applicant]
Coin et al. (2007) “Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences,” Nat. Protocols. 2:3247-. [cited by applicant]
Erlanson et al. (2000) “Site-directed ligand discovery,” Proc. Natl. Acad. Sci. USA. 97(17):9367-9372. [cited by applicant]
Gao et al. (2005) “Improved yields for baculovirus-mediated expression of human His6-PDK1 and His6-PKB-beta/Akt2 and characterization of phospho-specific isoforms for design of inhibitors that stabilize inactive conform… [cited by applicant]
Garcia-Echeverria et al. (2008) “Drug discovery approaches targeting the PI3K/Akt pathway in cancer,” Oncogene. 27:5511-5526. [cited by applicant]
Hirai et al. (2010) “MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo,” Molecular Cancer Therapeutics. 9(7):1956-1967. [cited by applicant]
Hiromura et al. (2004) “Inhibition of Akt Kinase Activity by a Peptide Spanning the beta-A Strand of the Proto-oncogene TCL1,” J. Biol. Chem. 279(51):53407-53418. [cited by applicant]
Jencks (1981) “On the attribution and additivity of binding energies,” Proc. Natl. Acad. Sci. USA. 78(7):4046-4050. [cited by applicant]
Jen-Jacobsen (1997) “Protein-DNA Recognition Complexes: Conservation of Structure and Binding Energy in the Trasintion State,” Biopolymers. 44:153-180. [cited by applicant]
Kijanka et al. (2009) “Rapid characterization of binding specificity and cross-reactivity of antibodies using recombinant human protein arrays,” J. Immunol. Methods. 340:132-137. [cited by applicant]
Kirkland et al. (2009) “Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics,” Biochem. Pharm. 77:1561-1571. [cited by applicant]
Klein et al. (2005) “Expression and purification of active PKB kinase from [cited by applicant]
Kumar et al. (2001) “Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling,” Biochim. Biophys. Acta. 1526:257-268. [cited by applicant]
Lam et al. (1991) “A new type of synthetic peptide library for identifying ligand-biding activity,” Nat. 354:82-84. [cited by applicant]
Lindsley et al. (2008) “The P13K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors,” Current Cancer Drug Targets. 8:7-18. [cited by applicant]
Manetsch et al. (2004) “In Situ Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications,” J. Am. Chem. Soc. 126:12809-12818. [cited by applicant]
Mason et al. (2007) “Positive Aspects of Negative Design: Simultaneous Selection of Specificity and Interaction Stability,” Biochem. 46:4804-4814. [cited by applicant]
Meyer et al. (2007) “Tethering Small Molecules to a Phage Display Library: Discovery of a Selective Bivalent Inhibitor of Protein Kinase A,” J. Am. Chem. Soc. 129:13812-13813. [cited by applicant]
Michaud et al. (2003) “Analyzing antibody specificity with whole proteome microarrays,” Nat. Biotechnol. 21:1509-1512. [cited by applicant]
Millward et al. (Sep. 30, 2011) “Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1,” J. Am. Chem. Soc. 133(45):18280-18288. [cited by applicant]
Mocharla et al. (2004) “In Situ Click Chemistry: Enzyme-Generated Inhibitors of Carbonic Anhydrase II,” Angew. Chem. Int. Ed. 44:116-120. [cited by applicant]
Murray et al. (2002) “The consequences of translational and rotational entropy lost by small molecules on binding to proteins,” J. Computer-Aided Mol. Design. 16:741-753. [cited by applicant]
Nguyen et al. (1998) “Exploiting the Basis of Proline Recognition by SH3 and WW Domains: Design of N-Substituted Inhibitors,” Science. 282:2088-2092. [cited by applicant]
Nguyen et al. (2000) “Improving SH3 domain ligand selectivity using a non-natural scaffold,” Chem. Biol. 7:463-473. [cited by applicant]
Niemeyer et al. (2005) “Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification,” Trends Biotechnol. 23:208-216. [cited by applicant]
Obata et al. (2000) “Peptide and Protein Library Screening Defines Optimal Substrate Motifs for AKT/PKB,” J. Biol. Chem. 275:36108-36115. [cited by applicant]
Posy et al. (2010) “Trends in Kinase Selectivity: Insights for Target Class-Focused Library Screening,” J. Med. Chem. 54:54-66. [cited by applicant]
Rebecchi et al. (1998) “Pleckstrin Homology Domains: A Common Fold with Diverse Functions,” Ann. Rev. Biophys. Biomol. 27:503-528. [cited by applicant]
Samson et al. (1995) “Identification of a Peptide Inhibitor Against Gal Phosphoglycerate Kinase of Trypanosoma brucei by a Synthetic Peptide Library Approach,” Bioorg. Med. Chem. 3:257-265. [cited by applicant]
Samson et al. (1997) “Protein Chemistry and Structure: Screening a Random Pentapeptide Library, Composed of 14 D-Amino Acids against the COOH-terminal Sequence of Fructose-1,6-bisphosphate Aldolase from Trypanosoma bruc… [cited by applicant]
Sarbassov et al. (2005) “Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex,” Science. 307 (5712):1098-1101. [cited by applicant]
Schildback et al. (1991) “Altered Hapten Recognition by Two Anti-digoxin Hybridoma Variants Due to Variable Region Point Mutations,” J. Biol. Chem. 266:4640-4647. [cited by applicant]
Shomin et al. (2009) “Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): Optimization and selectivity profiling,” Bioorg. Med. Chem. 17:6196-6202. [cited by applicant]
Shuker et al. (1996) “Discovering High-Affinity Ligands for Proteins: SAR by NMR,” Science. 274(5292):1531-1534. [cited by applicant]
Souroujon et al. (1998) “Peptide modulators of protein-protein interactions in intracellular signaling,” Nat. Biotech. 16:919-924. [cited by applicant]
Statsuk et al. (2008) “Tuning a Three-Component Reaction for Trapping Kinase Substrate Complexes,” J. Am. Chem. Soc. 130:17568-17574. [cited by applicant]
Subramanyam et al. (Feb. 26, 2010) “Inhibition of Protein Kinase Akt1 by Apoptosis Signal-regulating Kinase-1 (ASK1) Is Involved in Apoptotic Inhibition of Regulatory Volume Increase,” Journal of Biological Chemistry. 2… [cited by applicant]
Tornoe et al. (2002) “Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Termina Alkynes to Azides,” J. Organic Chem. 67:3057-3064. [cited by applicant]
Towbin et al. (1979) “Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications,” Proc. Natl. Acad. Sci. 76(9):4350-4354. [cited by applicant]
Vivanco et al. (2002) “The Phosphatidylinositol 3-Kinase—AKT Pathway in Human Cancer,” Nat. Rev. Cancer. 2:489-500. [cited by applicant]
Whiting et al. (2006) “Inhibitors of HIV-1 Protease by Using In Situ Click Chemistry,” Angew. Chem. Int. Ed. 45:1435-1439. [cited by applicant]
Xu et al. (2000) “Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities,” Immunity. 13:37-45. [cited by applicant]
Yang et al. (2004) “Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt,” Cancer Research. 64:4394-4399. [cited by applicant]
Zarrinpar et al. (2003) “Optimization of specificity in a cellular protein interaction network by negative selection,” Nature. 426:676-680. [cited by applicant]
Zemlin et al. (2003) “Expressed Murine and Human CDR-H3 Intervals of Equal Length Exhibit Distinct Repertoires that Differ in their Amino Acid Composition and Predicted Range of Structures,” J. Mol. Biol. 334:733-749. [cited by applicant]
Almehdi, et al., “SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies”, Infection, 49: 855-876 (2021). [cited by applicant]
He, et al., “Vaccine design based on 16 epitopes of SARS-CoV-2 spike protein”, Journal of Medical Virology, 93:2115-2131 (2021). [cited by applicant]
Yang, et al., “Structural biology of SARS-CoV-2 and implications for therapeutic development”, Nature Reviews, 19:685-700 (2021). [cited by applicant]
Muller, et al., “Folic acid conjugates for nuclear imaging of folate receptor-positive cancer”, J. Nucl. Med., 52: 1-4 (2011). [cited by applicant]
O'Shannessy, et al., “Characterization of the human folate receptor alpha via novel antibodybased probes”, Oncotarget, 2:1227-1243 (2011). [cited by applicant]
Agalave, et al., “Click chemistry: 1,2,3-triazoles as pharmacophores”, Chem. Asian J., 6: (10)2696-27018 (2011). [cited by applicant]
BPS Bioscience: INCB024360 Analog Data Sheet (2012). [cited by applicant]
Glaven, “Linking Single Domain Antibodies that Recognize Different Epitopes on the Same Target”, Biosensors, 2:43-56 (2012). [cited by applicant]
Kirszbaum, et al., “The alpha-chain of murine CD8 lacks an invariant Ig-like disulfide bond but contains a unique intrachain loop instead”, J. Immunol., 142(11):3931-6 (1989). [cited by applicant]
Koonin, et al., “Sequence—Evolution—Function: Computational Approaches in Comparative Genomics”, Boston: Kluwer Academic; 2003, Chapter 2 Evolutionary Concept in Genetics and Genomics (2003). [cited by applicant]
Reeck, et al., “‘Homolgy’ in Proteins and Nucleic Acids: A Terminology Muddle and a Way out of it”, Cell, 50:667 (1987). [cited by applicant]
Smith, et al., “Zinc mediated azide-alkyne ligation to 1,5- and 1,4,5-substituted 1,2,3-triazoles”, Org. Lett., 15(18):4826-4829 (2013). [cited by applicant]
Sormanni, et al., “Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins”, PNAS, 112(32):9902-9907 (2015). [cited by applicant]
Sormanni, etal., PNAS, 112(32):1-10, Supplemental Materials (2015). [cited by applicant]
Testa, et al., “CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies”, Biomarker Research, 2:4 (2014). [cited by applicant]
Wang, et al., “Structural basis of the CD8 alpha beta/MHC class I interaction: focused recognition orients CD8 beta to a T cell proximal position”, J. Immunol., 183(4):2554-64 (2009). [cited by applicant]